Business Wire

Mavenir Announces Industry’s Most Advanced Network Security and Fraud Management Suite

Jaa

Mavenir, focused on transforming mobile network economics for Communications Service Providers (CSPs), today announced its Network Security and Fraud Management Suite including a Fraud Management System equipped with big data analytics and advanced AI techniques such as machine learning and deep learning.

As operators continue to roll out new LTE-based services, Diameter signaling has become a new target for malicious attacks. Location tracking, interception of voice and text messages, denial of service on network and subscriber level, and other unauthorized activities are all potential use cases leading to fraudulent outcome that have occurred in the past with the SS7 protocol targeting 2G / 3G networks, and are also applicable to 4G networks, according to a recent report from the FCC’s Communications Security, Reliability and Interoperability Council (CSRIC).

Where security is compromised, fraud is inevitable. Traditional systems can no longer keep pace with the volume and velocity of criminal activity. Many existing systems can’t uncover new fraud types; they overwhelm the user with false positives or use dated rules that only uncover fraud long after it has taken place. Furthermore, the most impacting types and methods of fraud are related to subscription fraud, PBX hacking, international revenue share fraud, interconnect bypass, premium rate service.

Mavenir’s Security and Fraud Management Suite protects the network in real-time, and with predictive analytics and machine learning, the network is protected even as new vulnerabilities arise. Mavenir distinguishes between three main verticals within the fraud and security domain while providing the following corresponding solutions:

  • Messaging Revenue Assurance: Protects the CSPs’ revenue leakage based on innovative bypass techniques for A2P traffic. It offers efficient real-time detection of SPAM campaigns acknowledged by CSPs around the globe.
  • Network Signaling Security: Provides Signaling Firewalling solutions that implement the GSMA mitigation recommendations (FS.11 and FS.19) to detect and prevent the signaling-based attacks from happening.
  • Fraud Management: A modern data approach to fight fraud in real time. As part of its Security and Fraud Management Suite, Mavenir provides the Fraud Management Solution based on Big Data approach suited to manage the volume, velocity, and variety of structured and unstructured data over wireless networks. It relies on a unique, real-time fraud analytics platform, tailored for CSPs’ most pressing needs.

The key features of Mavenir’s Network Security and Fraud Management Suite include:

  • Easy-to-use / intuitive management interface for minimal response times to act on any unforeseen ongoing suspicious activity detected through sophisticated mitigation algorithms.
  • Powerful correlation engine offers detection of anomalous traffic patterns through efficient traffic profiling capabilities. The machine learning mechanisms behind the correlation engine create challenging obstacles for fraudulent activities to pass through unnoticed.
  • Supporting Analytics component enables CSPs to create interactive dashboards based on any required key performance indicators. The generated reports offer insights on the signaling traffic beyond security context helping the operators reveal any possible network optimizations or revise their interworking agreements.

“Malicious attacks are evolving with technology at a rapid pace and take revenue from operators. As a recent CFCA survey1 shows, global fraud levels translate into $29.2 billion global revenue loss for CSPs. Without sophisticated, adaptable, and self-learning security solutions, operators will forever be behind the technology curve with unprotected revenues,” said Pardeep Kohli, President and CEO of Mavenir. “We provide advanced cloud-native security for every type of messaging and signaling protocol used in the Telecom environment with anti-spam, anti-fraud solutions and firewall products.”

Mavenir’s cloud-native Security Suite includes Messaging (SMS, MMS, and RCS) Spam and Fraud control, Equipment Identity Register (EIR), Signaling Firewall (Diameter, SIP, SS7 and GTP), Session Border Controller (vSBC) and Mobile Edge Gateway (including ePDG, SeGW, and HeNB-GW) enabling operators to understand, monitor, enforce and maintain network security. The security suite fully covers protection of the core mobile network including the messaging revenue of modern CSPs.

Mavenir’s AI Center of Excellence is based in Brno, Czech Republic.

Visit Mavenir at 5G World in London from June 12th – 14th, 2018.

About Mavenir:

Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our innovative solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.

 
Mavenir, the M logo, and Cloud Range are trademarks owned by Mavenir Systems, Inc.
Copyright © 2017 Mavenir Systems, Inc. All Rights Reserved.
 

 

1   CFCA Global Fraud Loss Survey for 2017

Contact information

Mavenir
Maryvonne Tubb
PR@mavenir.com
or
MatterNow
Lydia Fakhouri
mavenir@matternow.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06Tiedote

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53Tiedote

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme